Tag Archives: devices

FDA Issues Guidance on Classification of Products as Drugs and Devices & Additional Product Classification Issues

FDA Issues Guidance on Classification of Products as Drugs and Devices & Additional Product Classification Issues

Full Text Here

FDA regularly receives requests from medical product developers concerning the classification of their products. We believe that efficient, effective regulation of such products is facilitated by providing guidance on issues frequently raised in relation to such requests. Certain issues have arisen often relating to whether a product should be classified as a drug or a device. Accordingly, this guidance focuses particularly on when a product may be classified as a drug or a device. This guidance also addresses additional issues relating to product classification, including how to obtain a formal classification determination from FDA for a medical product and the status of prior Agency determinations concerning product classification.
This guidance is organized into three substantive sections.
Section II offers guidance on the process to obtain a formal determination of whether a product is classified as a drug, device, biological product, or combination product.
Section III provides some general concepts for making classification determinations and addresses specific issues arise in determining whether products should be classified as drugs or devices

Section IV of this document provides an overview of the status of the current intercenter jurisdictional agreements, classifications that have been made by regulation, and classifications the Agency has made for a product that does not fall within the scope of a regulation, for example, by granting a marketing authorization or in responding to a request for designation.
The Agency recommends that manufacturers contact the Office of Combination Products (OCP) to confirm the classification of any products they may wish to market if the appropriate classification appears unclear for any reason. Section V provides contact information for OCP.

For Assistance with Development of Drug Device Combinations Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

MHRA Publish Guidance on Clinical Trials for Devices

MHRA Publish Guidance on Clinical Trials for Devices

These Notes outline the legal requirements relating to the conduct and performance of a clinical investigation as set out in these Regulations. They also provide background and guidance to manufacturers on how to apply for pre-clinical assessment of a proposed clinical investigation in human subjects, involving a device falling within the scope of the Regulations.

Manufacturers wishing to make an application for pre-clinical assessment of a proposed clinical investigation of an active implantable medical device or a medical device to be carried out in part or in whole in the UK should apply to the Medicines & Healthcare products Regulatory Agency of the Department of Health (referred to in this document as the UK Competent Authority), in accordance with these Guidance Notes.

This guidance is intended as a general explanation of the legislation and should not be regarded as an authoritative statement of the law nor as having any legal consequence. It follows that manufacturers and others should not rely solely on this guidance but should consult the legislation referred to and make their own decisions on matters affecting them in conjunction with their lawyers and other professional advisers. The MHRA does not accept liability for any errors, omissions or other statements in the guidance whether negligent or otherwise. An authoritative statement could
be given only by the courts. Information and assistance in individual cases may be sought from the UK Competent Authority whose address and telephone number are given on pages 12 – 13 of this document.

For Assistance with the development of a medical device Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

Fill Out the Short Form Below…


  1. (required)


  2. (valid email required)

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

MHRA, The UK Drug Regulator, Pubilshes Guidance for Manufactures on Clinical Investigations To Be Carried Out in the UK

MHRA, The UK Drug Regulator, Publishes Guidance for Manufactures on Clinical Investigations To Be Carried Out in the UK.

Full Text Here

1. The Medical Devices Regulations 2002 (SI No 618), as amended by the Medical Devices (Amendment) Regulations 2008, came into force on 13 June 2002 and implement the provisions of the Medical Devices Directive 93/42/EEC (as amended by Directive 2007/47/EC), the Active Implantable Medical Devices Directive 90/385/EEC (as amended by Directive 2007/47/EC) and the In Vitro Diagnostic Medical Devices Directive 98/79/EEC. These Regulations establish systems under which a manufacturer must submit to the UK Competent Authority, information about clinical investigations of medical devices to be carried out in the UK. 2. These Notes outline the legal  requirements relating to the conduct and performance of a clinical investigation as set out in these Regulations. They also provide background and guidance to manufacturers on how to apply for pre-clinical assessment of a proposed clinical investigation in human subjects, involving a device falling within the scope of the
Regulations.

3. Manufacturers wishing to make an application for pre-clinical assessment of a proposed clinical investigation of an active implantable medical device or a medical device to be carried out in part or in whole in the UK should apply to the Medicines & Healthcare products Regulatory Agency of the Department of Health (referred to in this document as the UK Competent Authority), in accordance with these Guidance Notes.

4. This guidance is intended as a general explanation of the legislation and should not be regarded as an authoritative statement of the law nor as having any legal consequence. It follows that manufacturers and others should not rely solely on this guidance but should consult the legislation referred to and make their own decisions on matters affecting them in conjunction with their lawyers and other professional advisers. The MHRA does not accept liability for any errors, omissions or other statements in the guidance whether negligent or otherwise. An authoritative statement could be given only by the courts. Information and assistance in individual cases may be sought from the UK Competent Authority whose address and telephone number are given on pages 12 – 13 of this document.

For Regulatory Services Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Drug Regulator FDA, Publishes Guidance on the Use of Bayesian Statistics in Medical Device Clinical Trials

Drug Regulator FDA, Publishes Guidance on the Use of Bayesian Statistics in Medical Device Clinical Trials

Full Text Here

This document provides guidance on statistical aspects of the design and analysis of clinical trials for medical devices that use Bayesian statistical methods.
The purpose of this guidance is to discuss important statistical issues in Bayesian clinical trials for medical devices. The purpose is not to describe the content of a medical device submission. Further, while this document provides guidance on many of the statistical issues that arise in Bayesian clinical trials, it is not intended to be all-inclusive. The statistical literature is rich with books and papers on Bayesian theory and methods; a selected bibliography has been included for further discussion of specific topics.

Click Here – Regulatory Services – Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

ida consultants freestrategyconsultation 515x64 Drug Regulator FDA, Publishes Guidance on the Use of Bayesian Statistics in Medical Device Clinical Trials

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

ida 100programme 515x64 LowRes Drug Regulator FDA, Publishes Guidance on the Use of Bayesian Statistics in Medical Device Clinical Trials

Drug Regulators, FDA, Publish Guidance on the Use of Bayesian Statistics in Medical Device Clinical Trails.

Drug Regulators, FDA, Publish Guidance on the Use of Bayesian Statistics in Medical Device Clinical Trails.

Full Text Here

This document provides guidance on statistical aspects of the design and analysis of clinical trials for medical devices that use Bayesian statistical methods.
The purpose of this guidance is to discuss important statistical issues in Bayesian clinical trials for medical devices. The purpose is not to describe the content of a medical device submission. Further, while this document provides guidance on many of the statistical issues that arise in Bayesian clinical trials, it is not intended to be all-inclusive. The statistical literature is rich with books and papers on Bayesian theory and methods; a selected bibliography has been included for further discussion of specific topics.

Click – Development Services – Click

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

ida consultants freestrategyconsultation 515x64 Drug Regulators, FDA, Publish Guidance on the Use of Bayesian Statistics in Medical Device Clinical Trails.

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

ida 100programme 515x64 LowRes Drug Regulators, FDA, Publish Guidance on the Use of Bayesian Statistics in Medical Device Clinical Trails.

MHRA publishes guidance on the Medical Devices Directives

The MHRA has published Guidance on the EC Medical Devices Directives.

The guidance document is a comprehensive document, and covers the regulations in some detail:

  • The Medical Devices Regulations 2002
  • The Active Implantable Medical Devices Directive
  • Medical Devices Directive
  • In Vitro Diagnostic Medical Devices Directive

The Guidance provides help interpreting these regulations in a number of Specific Areas:

  • Clinical Investigtions in the UK
  • Is a Clinical Investigation Required
  • Special Clinical Investigations
    • Changes in intended use
    • Comparative Studies
    • Prototype Devices
    • Clinical Investigations also submitted to the FDA of other Non-EU Regulatory Authorities
    • In-house manufactured medical devices
    • “Off-Label” use
  • Making an Application for Pre-clinical Assessment
  • Competent authority processing of the clinical investigation
  • Documentation required for all submissions
  • Clinical Investigational Plans
  • Documentation to be kept available
  • Special features of clinical trials
  • How your application will be handled by the UK-competent authority
  • Adverse event handling

The publication is detailed and covers a number of areas in detail, it is recommended reading for anybody developing a medical device.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug  development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

ida consultants freestrategyconsultation 515x64 MHRA publishes guidance on the Medical Devices Directives

As you know this website is a great resourse for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.